Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.390
-0.110 (-7.33%)
At close: Mar 9, 2026
Duopharma Biotech Berhad Balance Sheet
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 290.87 | 264.55 | 270.5 | 157.64 | 137.98 | Upgrade
|
| Cash & Short-Term Investments | 290.87 | 264.55 | 270.5 | 157.64 | 137.98 | Upgrade
|
| Cash Growth | 9.95% | -2.20% | 71.60% | 14.25% | -12.69% | Upgrade
|
| Accounts Receivable | 223.8 | 184.33 | 135.04 | 131.31 | 122.42 | Upgrade
|
| Other Receivables | 11.57 | 23.59 | 26.38 | 10.84 | 10.31 | Upgrade
|
| Receivables | 235.37 | 207.92 | 161.42 | 142.15 | 132.72 | Upgrade
|
| Inventory | 293.17 | 248.55 | 243.07 | 235.18 | 222.19 | Upgrade
|
| Prepaid Expenses | - | 5.39 | 2.08 | 6.52 | 1.9 | Upgrade
|
| Total Current Assets | 819.41 | 726.4 | 677.07 | 541.49 | 494.8 | Upgrade
|
| Property, Plant & Equipment | 554.08 | 567.52 | 582.37 | 579.92 | 542.53 | Upgrade
|
| Long-Term Investments | 16.48 | 22.67 | 36.91 | 42.15 | 73.54 | Upgrade
|
| Other Intangible Assets | 36.88 | 7.32 | 7.65 | 3.84 | 4.95 | Upgrade
|
| Long-Term Deferred Tax Assets | 20.4 | 15.33 | 8.95 | 13.33 | 12.7 | Upgrade
|
| Long-Term Deferred Charges | - | 37.55 | 31.15 | 40.14 | 34.58 | Upgrade
|
| Other Long-Term Assets | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | Upgrade
|
| Total Assets | 1,448 | 1,378 | 1,345 | 1,222 | 1,164 | Upgrade
|
| Accounts Payable | 162.24 | 55.89 | 40.45 | 51.93 | 31.32 | Upgrade
|
| Accrued Expenses | - | 46.92 | 33.79 | 40.46 | 61.2 | Upgrade
|
| Short-Term Debt | - | 32.33 | 50.59 | 101.8 | 87.85 | Upgrade
|
| Current Portion of Long-Term Debt | 147.42 | 15.66 | 14.95 | 32.34 | 15.08 | Upgrade
|
| Current Portion of Leases | - | 0.55 | 0.92 | 0.94 | 0.64 | Upgrade
|
| Current Income Taxes Payable | 4.29 | 0.74 | 0.37 | 1.17 | 6.06 | Upgrade
|
| Other Current Liabilities | - | 25.89 | 25.65 | 35.95 | 28.17 | Upgrade
|
| Total Current Liabilities | 313.96 | 177.99 | 166.73 | 264.59 | 230.31 | Upgrade
|
| Long-Term Debt | 345.47 | 464.52 | 480.9 | 294.6 | 297.8 | Upgrade
|
| Long-Term Leases | 2.82 | 2.76 | 1.48 | 1.92 | 2.48 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 28.43 | 23.42 | 8.91 | 5.58 | 9.54 | Upgrade
|
| Total Liabilities | 690.68 | 668.68 | 658.01 | 566.7 | 540.13 | Upgrade
|
| Common Stock | 432.47 | 432.47 | 432.47 | 419.37 | 405.86 | Upgrade
|
| Retained Earnings | 408.57 | 354.78 | 319.07 | 288.37 | 239.97 | Upgrade
|
| Comprehensive Income & Other | -83.41 | -78.09 | -64.41 | -52.52 | -21.82 | Upgrade
|
| Shareholders' Equity | 757.62 | 709.15 | 687.12 | 655.22 | 624 | Upgrade
|
| Total Liabilities & Equity | 1,448 | 1,378 | 1,345 | 1,222 | 1,164 | Upgrade
|
| Total Debt | 495.72 | 515.82 | 548.85 | 431.6 | 403.84 | Upgrade
|
| Net Cash (Debt) | -204.85 | -251.28 | -278.35 | -273.97 | -265.86 | Upgrade
|
| Net Cash Per Share | -0.21 | -0.26 | -0.29 | -0.29 | -0.29 | Upgrade
|
| Filing Date Shares Outstanding | 961.94 | 961.94 | 961.94 | 952.24 | 941.77 | Upgrade
|
| Total Common Shares Outstanding | 961.94 | 961.94 | 961.94 | 952.24 | 941.77 | Upgrade
|
| Working Capital | 505.45 | 548.42 | 510.34 | 276.9 | 264.49 | Upgrade
|
| Book Value Per Share | 0.79 | 0.74 | 0.71 | 0.69 | 0.66 | Upgrade
|
| Tangible Book Value | 720.74 | 701.84 | 679.47 | 651.38 | 619.06 | Upgrade
|
| Tangible Book Value Per Share | 0.75 | 0.73 | 0.71 | 0.68 | 0.66 | Upgrade
|
| Land | - | 65.68 | 65.68 | 69.88 | 69.88 | Upgrade
|
| Buildings | - | 267.09 | 265.86 | 125.23 | 124.51 | Upgrade
|
| Machinery | - | 452.39 | 435.18 | 368.47 | 308.94 | Upgrade
|
| Construction In Progress | - | 12.19 | 8.48 | 172.65 | 162.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.